Drug Database
Back to search

Netherlands· NL-6814c49eee06

Cometriq 80 mg, capsule, hard

A cabozantinib product containing cabozantinib (s)-malaat, registered in Netherlands by Ipsen Pharma. The same ATC class is registered in 12 of our 19 countries.

ATC L01EX07

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedCometriq 80 mg, capsule, hardATCL01EX07REGISTER NO.NL-6814c49eee06PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about cabozantinib (s)-malaatAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Cabozantinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EX07 (cabozantinib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search cabozantinib products by name

Cabozantinib · ATC L01EX07

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cabozantinib costs, country by country.

Normalised to the WHO defined daily dose (60 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Cabozantinib · price per daily dose (60 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$570.30
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
CABOZANTINIB (S)-MALAAT
Manufacturer
Ipsen Pharma
Country
Netherlands (NL)
ATC code
L01EX07
ATC class
Cabozantinib
Defined daily dose
60 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/13/890

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

544 interactions on record for cabozantinib.

Graded by severity as the source publishes them — 360 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check cabozantinib against other medicinesHow interaction checks work

Cabozantinib · interactions on record

544 records

  • 360 severe
  • 179 moderate
  • 5 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under L01EX07

Cabozantinib, as other registers publish it.

All cabozantinib products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dc301d6d-122d-408d-b1d1-49c417e28ff7
GET /v1/drugs/dc301d6d-122d-408d-b1d1-49c417e28ff7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/cometriq-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Cabozantinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp112850",
  "excipients": [
    "AMMONIA (E 527)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "GELATINE (E 441)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "NATRIUMZETMEELGLYCOLAAT",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK GLAZE, GEDEELTELIJK VERESTERD",
    "SILICIUMDIOXIDE (E 551)",
    "STEARINEZUUR (E 570)",
    "TITAANDIOXIDE (E 171)",
    "ZWARTE INKT"
  ],
  "substances": [
    "CABOZANTINIB (S)-MALAAT"
  ],
  "leaflet_url": null,
  "authorised_at": "2014/03/21",
  "procedure_number": "EMEA/H/C/002640",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/13/890",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about cabozantinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console